Managing debilitating menopausal symptoms

O’Sullivan M, Overton C. Managing debilitating menopausal symptoms. 
Practitioner 2016;260(1791):17-21
Managing debilitating menopausal symptoms

How should women be assessed?

Most women will experience some menopausal symptoms. The severity and duration of these symptoms can vary markedly between individuals. Around eight out of ten women will experience symptoms and on average these last four years, with one in ten women experiencing symptoms for up to 12 years. Hence it is important to take an individualised approach to their assessment and management. Women tend to seek medical advice when their symptoms start to affect their ability to function at home or work and/or affect relationships. Common menopausal symptoms are listed in table 1, p18.

What are the management options?

Avis and colleagues analysed data on 1,449 women with frequent vasomotor symptoms who took part in the Study of Women’s Health across the Nation, an observational study from the USA. All reported having frequent hot flushes and night sweats for at least six days in the past two weeks. These symptoms lasted for a median total duration of 7.4 years, but generally the earlier symptoms started the longer they continued. Those women whose vasomotor symptoms started before the menopause suffered longest.

Which women should be referred?

How

should women
be assessed?

Vasomotor symptoms
Consider FSH if aged 40-45 with menopausal symptoms or if <40 and premature menopause suspected

Offer HRT after discussion of the short- and long-term risks and benefits
Explain there is some evidence for the use of isoflavones and black cohosh but that preparations are unlicensed and variable

Consider HRT for low mood and anxiety
Consider CBT
Do not prescribe SSRIs/SNRIs for low mood unless there is clinical depression

Consider testosterone supplementation if libido does not improve with HRT

Offer topical oestrogens, even to those on systemic HRT. Topical oestrogens should also be considered for women in whom systemic HRT is contraindicated after seeking specialist advice

Psychological symptoms
Provide women with information on menopausal signs, symptoms and stages
Give women information on the hormonal, pharmacological and non-pharmacological treatments available for treatment of menopausal symptoms

Assess after three months and then annually
Refer to a specialist when HRT is contraindicated or if symptoms persist

Sexual dysfunction

Consider contraceptive and sexual health needs

Urogenital atrophy

AUTHORS
Dr Marie O’Sullivan
MB ChB
Specialist Registrar in Obstetrics & Gynaecology

Mrs Caroline Overton
MBBS MD FRCOG FHEA
Consultant Gynaecologist & Subspecialist in Reproductive Medicine & Laparoscopic Surgery
St Michael’s University Hospital, Bristol, UK

FIGURE 1
Pathway for the management of menopausal symptoms
Table 2

<table>
<thead>
<tr>
<th>Common menopausal symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Hot flushes and night sweats</td>
</tr>
<tr>
<td>• Difficulty sleeping</td>
</tr>
<tr>
<td>• Decreased sex drive</td>
</tr>
<tr>
<td>• Vaginal dryness; discomfort during sex</td>
</tr>
<tr>
<td>• Problems with memory and concentration</td>
</tr>
<tr>
<td>• Mood changes, such as low mood or anxiety</td>
</tr>
<tr>
<td>• Joint stiffness, aches and pains</td>
</tr>
<tr>
<td>• Recurrent urinary tract infections</td>
</tr>
</tbody>
</table>

Table 2

<table>
<thead>
<tr>
<th>Risks of HRT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Venous thromboembolism (VTE)</strong></td>
</tr>
<tr>
<td>Oral HRT increases background VTE risk 2-4 fold with the highest risk in the first year of use. Women at high risk of VTE (e.g. a family history of VTE, obesity) should be offered transdermal HRT as this is not associated with increased VTE risk.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence on HRT and stroke is conflicting and HRT may slightly increase baseline risk. HRT should be used with caution in those at high risk and cannot be recommended for stroke prevention. The transdermal route may be preferable for those at higher risk.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiovascular disease (CVD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRT does not increase the risk of death from CVD when started in women under the age of 60.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast:</strong> The WHI trial found that combined oestrogen and progesterone was associated with a slight increased risk of breast cancer (one extra case per 1,000 women per year). Risk returns to baseline five years after stopping HRT.</td>
</tr>
</tbody>
</table>

| Ovarian: |
| Data conflicting |

| Endometrial: |
| Increased risk if unopposed oestrogen used in women with a uterus, no increased risk if combined HRT used |

| Colorectal: |
| Decreased incidence (data for oral administration only) |

| HRT after cancer: |
| No evidence that HRT after ovarian, endometrial, cervical or vulval cancers affects recurrence or prognosis |

median 11.8 years. Women whose hot flushes and night sweats started after the menopause fared better reporting symptoms with a median of 3.4 years’ duration.

Black women reported the longest duration of symptoms (median 10.1 years). Japanese and Chinese women suffered the shortest length of time (median 4.8 and 5.4 years, respectively). Among White women 6.5 years was the median duration, and among Hispanic women it was 8.9 years.

**ASSESSMENT**

It is important to gauge the severity of the woman’s symptoms and establish which she finds most bothersome so that treatment can be tailored to the individual once the options have been discussed, see figure 1, p17.

‘Testing for FSH levels should only be considered in women aged 40-45 with menopausal symptoms or those under 40 with suspected early menopause’

Menopausal symptoms can begin months or even years before menstruation ceases. Menopausal status needs to be evaluated based on history and symptoms. The perimenopause can be diagnosed on the basis of symptoms and irregular periods in women with a uterus, and symptoms alone in women who have had a hysterectomy. Testing for FSH levels should only be considered in women aged 40-45 with menopausal symptoms or those under 40 with suspected early menopause. Postmenopausal status can be diagnosed in women who are not on hormonal contraception who have not had a period for 12 months.

**MANAGEMENT**

**Hormone replacement therapy**

In general, the benefits of short-term HRT outweigh the risks in the majority of symptomatic women, especially in those under the age of 60. There is currently no evidence that HRT confers any cardiovascular protection (or harm) or protection against the development of dementia although some women feel that HRT helps with their cognition.

Cardiovascular risk should be assessed. Women with cardiovascular disease are not necessarily unsuitable for HRT but need their cardiovascular health optimised. In those women with a high risk of venous thromboembolism (VTE) a thrombophilia screen should be considered (although even if this is negative, it does not absolve risk).

If there is a history of arterial disease a lipid profile should be considered.

If there is a high risk of breast cancer, counsel the woman with regards to her risk and consider referring for mammography. HRT can be started without examination or investigation unless there are concerns about gynaecological cancers (sudden change in menstrual pattern, post-coital bleeding, intermenstrual bleeding, history or strong family history of gynaecological cancers).

In the 1970s, it was believed that HRT offered protection against heart disease and cognitive decline. Following the publication of findings from the Million Women’s study in 2003 it was recognised that there was a significant
breast cancer risk with HRT.

This large UK study found that use of HRT by women aged 50-64 over the previous decade had resulted in an estimated 20,000 extra cases of breast cancer, 15,000 associated with oestrogen-progestogen combined HRT.

The risks of HRT are listed in table 2, opposite, and the risk of breast cancer with various forms of HRT in table 3, above.

‘Generally the earlier [vasomotor] symptoms started the longer they continued’

Without HRT, symptoms tend to improve over five to ten years. Although HRT can ameliorate menopausal symptoms, on stopping therapy the symptoms can return.

Patches are used continuously starting within five days of menstruation (or at any time if periods have stopped or are infrequent). Patches should be removed after three to four days (or once a week in the case of the seven-day patch) and replaced with a fresh patch on a slightly different site. Recommended sites are clean, dry, unbroken areas of skin on the trunk below the waistline. Patches should not be applied on or near the breasts or under the waistband. Patches should not be applied on or near the skin on the trunk below the waistline.

Patches should be applied on or near the breasts or under the waistband. If a patch falls off in the bath, the woman should allow the skin to cool before applying a new patch.

Tablets can be started on day one of the period (or at any time if periods have stopped or are infrequent). For women with a uterus, progestogen is required to prevent endometrial hyperplasia and possible transformation to cancer.

Progestogen appears to be a tumour promoter, particularly with respect to the breast. It can be delivered by the following routes:

- Orally for 14 days every month
- Orally for 14 days every three months
- Orally as a daily tablet or capsule
- Transdermally as a patch
- As an IUS

HRT does not provide contraception and a woman is potentially fertile for two years after her last menstrual period if she is under 50 and for one year if she is over 50. A woman who is under 50 and has a low VTE risk can use a low-oestrogen combined oral contraceptive pill to provide both relief of menopausal symptoms and contraception.

Consider stopping the contraceptive pill at the age of 50, as there may be a more suitable alternative e.g. the progestogen-only pill. If any potentially fertile woman needs HRT, non-hormonal contraceptive measures, such as condoms, are needed if she is sexually active.

HRT should be stopped immediately if any of the following occur:

- Sudden severe chest pain (even if not radiating to the left side)
- Sudden breathlessness (or cough with bloodstained sputum)
- Severe stomach pain
- Unexplained swelling or severe pain in the calf of one leg
- Serious neurological defects including: unusual severe, prolonged headache especially if this is the first time, or getting progressively worse; sudden, partial or complete loss of vision; sudden disturbance of hearing; other perceptual disorders; dysphasia; or bad fainting attack; collapse; first unexplained epileptic seizure or weakness; motor disturbances; very marked numbness suddenly affecting one side or one part of the body
- Hepatitis, jaundice, liver enlargement
- Raised blood pressure - systolic > 160 mmHg or diastolic > 95 mmHg
- Prolonged immobility after surgery or leg injury
- Detection of a risk factor that contraindicates treatment

Reported side effects of HRT include:

- Nausea, vomiting, abdominal cramps
- Ballooning and weight changes
- Breast enlargement and tenderness
- Premenstrual-like syndrome
- Sodium and fluid retention
- Cholestatic jaundice
- Glucose intolerance
- Altered blood lipids - may lead to pancreatitis, rashes
- Chloasma
- Changes in libido, depression, mood changes
- Headache, migraine, dizziness
- Leg cramps (rule out venous thrombosis)
- Vaginal candidiasis
- Contact lenses may irritate
- Transdermal delivery systems may cause contact sensitisation (possible severe hypersensitivity reaction on continued exposure)
- Headache has been reported on vigorous exercise

Other treatments

Despite evidence supporting the safety profile of HRT, not all women wish to use it. This has led to the ongoing pursuit of alternative treatments outlined in table 4, p20.

Traditional HRT helps symptoms in 80-90% of women compared with 50-60% of women on alternative treatment.7 Many alternative therapies interact with other medication and there is a lack of data on potential adverse effects. GPs should inform women that alternative medicines do not undergo the same regulations and licensing as pharmacological drugs.

Ovarian production of sex steroid hormones continues to some degree after the menopause, consequently those that undergo bilateral oophorectomy often suffer more with low libido.

Tibolone is a synthetic steroid with oestrogenic, progestogenic and androgenic properties. It is sometimes recommended for younger women, especially those with low libido.
A petit pois sized amount of gel should be applied to clean, dry unbroken skin. There have been reports of localised hypertrichosis, so women should apply the gel on areas where hair growth is less critical e.g. the lower leg. There is no evidence that testosterone increases breast cancer risk.8 Side effects of acne and hirsutism are related to dose and duration of use and usually resolve once treatment is discontinued.

Once HRT is started, women should be assessed at three months to determine whether HRT is effective and to check for side effects. Thereafter, women should be reviewed annually.

**REFERRAL**
Women should be referred to a specialist if HRT does not relieve symptoms or side effects are a problem. Referral should also be considered if there is uncertainty as to the best HRT or if there are contraindications to HRT such as oestrogen-dependent cancer, a history of breast cancer, active

### Table 4
#### Summary of alternative approaches3,7

<table>
<thead>
<tr>
<th>Lifestyle measures</th>
<th>Non-pharmacological treatments for vaginal dryness</th>
<th>Alpha-2 agonists (clonidine)</th>
<th>SSRIs/SNRIs</th>
<th>Gabapentin</th>
<th>Cognitive behaviour therapy</th>
<th>Progestogens</th>
<th>Topical progesterone cream</th>
<th>Phyto-oestrogens/soy/red clover</th>
<th>Herbal medicines e.g. St. John’s Wort and evening primrose oil</th>
<th>Acupuncture/osteopathy/Reiki</th>
<th>Vitamins such as C and E</th>
<th>Stellate ganglion blockade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerobic exercise</td>
<td>Gels/lubricants</td>
<td>Not effective at relieving vasomotor symptoms in all trials and their use is limited because of the side effects, can be tried first line for women with hypertension</td>
<td>Significantly better than placebo - best effect from venlafaxine (SNRI)</td>
<td>Effective in reducing hot flushes compared with placebo</td>
<td>Effective in the management of low mood or anxiety</td>
<td>Effective in reducing hot flushes but increased breast cancer and VTE risk</td>
<td>Conflicting evidence. Not suitable for use for endometrial protection</td>
<td>Conflicting evidence, should be avoided if history of breast cancer. Some evidence that isoflavones and black cohosh may relieve vasomotor symptoms’ but preparations are unlicensed and variable. May interact with other drugs</td>
<td>No supporting evidence. May interact with other drugs</td>
<td>No supporting evidence</td>
<td>Limited evidence of benefit</td>
<td>Promising, especially when all else contraindicated</td>
</tr>
</tbody>
</table>
The severity and duration of menopausal symptoms can vary markedly between individuals. Around 80 per cent of women will experience symptoms and on average these last four years, with one in ten women experiencing symptoms for up to 12 years. A large study found that women whose vasomotor symptoms started before the menopause suffered longest, median 11.8 years. Women whose hot flushes and night sweats started after the menopause had symptoms for a median of 3.4 years.

Menopausal symptoms can begin months or years before menstruation ceases. Menopausal status needs to be evaluated based on history and symptoms. The perimenopause can be diagnosed on the basis of symptoms and irregular periods in women with a uterus, and symptoms alone in women who have had a hysterectomy. Testing for FSH levels should only be considered in those aged 40-45 with menopausal symptoms or those under 40 with suspected early menopause. Postmenopausal status can be diagnosed in women who are not on hormonal contraception who have not had a period for 12 months.

In general, the benefits of short-term HRT outweigh the risks in the majority of symptomatic women, especially in those under 60. There is no evidence that HRT confers any cardiovascular protection (or harm) or protection against the development of dementia. Cardiovascular risk should be assessed. Women with cardiovascular disease are not necessarily unsuitable for HRT but need their cardiovascular health optimised. In those women with a high risk of venous thromboembolism (VTE) a thrombophilia screen should be considered (although even if this is negative, it does not absolve risk). If there is a history of arterial disease a lipid profile should be considered. If there is a high risk of breast cancer, counsel the woman with regards to her risk and consider referring for mammography.

HRT does not provide contraception and a woman is potentially fertile for two years after her last menstrual period if she is under 50 and for one year if she is over 50. A woman who is under 50 and has a low VTE risk can use a low-oestrogen combined oral contraceptive pill to provide both relief of menopausal symptoms and contraception.

Women should be referred to a specialist if HRT does not relieve symptoms or side effects are a problem. Referral should also be considered if there is uncertainty as to the best HRT or if there are contraindications to HRT such as oestrogen-dependent cancer, history of invasive breast cancer, active thrombophlebitis, active or recent arterial thromboembolic disease (e.g. angina or myocardial infarction), venous thromboembolism, recurrent thromboembolism (unless already on anticoagulant treatment), thrombophilic disorder, liver disease (where liver function tests have failed to return to normal), Dubin-Johnson syndrome and Rotor syndrome (or monitored closely), untreated endometrial hyperplasia, undiagnosed vaginal bleeding.

CONCLUSION
The perimenopause can be a distressing and debilitating time for some women. The latest evidence supports the use of HRT for many women, if they wish to use it and women should be supported in making an informed choice.

Further research is needed to assess the efficacy and safety of alternative therapies. Specialist referral pathways should be in place for complex patients and where first-line therapies have failed or there are contraindications to HRT.

REFERENCES
1 NICE. Clinical Knowledge Summaries http://cks.nice.org.uk/menopause. Last revised October 2015
2 Avis NE, Crawford SL, Greendale G et al. Study of Women’s Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175(4):539-91
5 Writing group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomised controlled trial. JAMA 2002;288:321-33
7 Embrechts in Lancet 2003;362(9380):180

Useful information
The British Menopause Society Useful factsheets www.thebms.org.uk/factsheets.php

We welcome your feedback
If you wish to comment on this article or have a question for the authors, write to: editor@thepractitioner.co.uk